
Scott Whitaker Op-Ed: Tariffs Should Spare Vital U.S. MedTech Industry
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
2025 Emerging Policy Response Resources
A powerful op-ed from AdvaMed’s CEO explaining why tariffs could undermine U.S. medtech innovation, jobs, and patient care—and what must be done.
AdvaMed’s Q1 2025 report focuses on tariffs, policy action, and how we’re protecting Medtech innovation.
WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:
Details a sweeping tariff hike to 84% on Chinese imports and de minimis increases, aiming to protect U.S. economic and national security.
Washington, D.C.– AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker: “Our country is the birthplace of the medical device and technology industry and leads the…
Exclusive member webinar on tariffs, customs, USMCA rules of origin, and compliance strategies with expert Larry Friedman. Air Date April 4, 2025. Now On Demand!
Tariffs on medical goods threaten healthcare costs, access, and supply chains. Leading health groups urge exemptions to safeguard patient care.
Tariffs on medtech could disrupt supply chains, increase costs, and delay care. Exemptions are needed to protect hospitals, patients, and innovation.
An overview of the Make America Healthy Again Commission, its mission to address chronic disease in the U.S., and policy initiatives aimed at improving public health.
A breakdown of the administration’s trade policy, highlighting key areas where the U.S. seeks to level the playing field with trading partners through reciprocal tariffs.